A Phase I Study of Mozobil(Trademark) in the Treatment of Patients With WHIMS
- WHIMS (warts, hypogammaglobulinemia, infection, and myelokathexis syndrome) is caused by various genetic changes that increase the activity of the CXCR4 gene. Excessive function of this gene causes mature neutrophils (part of white blood cells) to be retained within the bone marrow rather than being released to the general blood circulation, and is one of the causes of severe inherited neutropenia (low white blood counts). In neutropenia, the body is less able to fight off infection. Patients with WHIMS usually are at risk for skin, soft tissue, sinus, and lung infections, which can result in loss of hearing, teeth, and lung function.
- Current treatment for WHIMS consists of regular injections of a white blood cell growth stimulating medication called granulocyte colony stimulating factor (G-CSF), and monthly infusions of intravenous immunoglobulin (IVIG). These therapies are expensive, nonspecific, have significant side effects and toxicities, and do not fully correct all problems, especially warts and cancers related to human papillomavirus (HPV).
- A drug called Mozobil(Trademark) has been approved for use in combination with G-CSF to increase the number of stem cells that can be collected prior to bone marrow transplantation. Mozobil(Trademark) may offer a specific and well-tolerated new treatment for WHIMS and other syndromes characterized by neutropenia.
- To evaluate whether Mozobil(Trademark) is safe and effective to treat neutropenia (low white blood cell count) in patients with WHIMS.
- To determine an appropriate treatment dose of Mozobil, within currently approved dosage levels.
- Individuals between 18 and 75 years of age who have been diagnosed with WHIMS and have a history of severe infections.
- Potential participants will undergo a screening study, with a medical history, physical examination, questionnaire, heart and lung function scans, and blood and urine samples. Tests will also be done for hepatitis B and C virus, and human immunodeficiency virus (HIV) that causes acquired immunodeficiency syndrome (AIDS), as well as to check neutrophil function.
- Patients who are being treated with G-CSF will stop injections for 5 days before being admitted to the National Institutes of Health (NIH) Clinical Center. While off the medication, patients will keep a diary to report information about their general well-being while off the medications and will bring it to NIH when admitted.
- Patients will be admitted to the NIH Clinical Center inpatient until 2 days before starting the treatment and will stay for approximately 10 days. Before the treatment, patients will have blood samples taken regularly.
- Patients will receive increasing doses of Mozobil over 5 days of treatment until their white blood cell count improves sufficiently or the maximum approved dose is reached. Blood samples will be taken regularly throughout the treatment process. Patients will then receive an additional dose of Mozobil at the maximum approved dose or the dose sufficient to cause improvement, before restarting the G-CSF injections.
- Between 4 and 6 weeks after the treatment phase, patients will return to the NIH for an outpatient study completion and evaluation visit.
Drug: Mozobil (TM)
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase I Study of Mozobil (TM) in the Treatment of Patients With WHIMS|
- Determine whether or not Mozobil (TM) is safe in study population.
- Whether or not treatment results in increased ANC.
|Study Start Date:||July 2009|
|Estimated Study Completion Date:||June 2014|
|Estimated Primary Completion Date:||June 2014 (Final data collection date for primary outcome measure)|
Drug: Mozobil (TM)
Mozobil (TM) (plerixafor injection, Genzyme Corp.) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myeloma when used in conjunction with granulocyte-colony stimulating factor (G-CSF). The drug's mechanism of action is the specific and reversible inhibition of the chemokine receptor, CXCR4, expressed on CD34+ cells and other leukocytes. This inhibition interferes with the binding of stromal cell derived factor-1 (SDF-1), which is constitutively expressed on bone marrow stromal cells and appears to cause direct and indirect cellular adhesive interactions. Severe congenital neutropenia is a rare inherited disorder in which the affected individuals develop chronic or cyclical neutropenia with circulating counts below 500 cells/microliter blood. This disorder may result from a variety of genetic defects in progenitor- or neutrophil-expressed genes such as elastase, CXCR4, G6PC3, etc. Myelokathexis is the abnormal retention of mature leukocytes in the bone marrow and is seen in some types of severe chronic neutropenia such as warts, hypogammaglobulinemia, infections, and myelokathexis syndrome (WHIMS). WHIMS is a rare primary immunodeficiency, which is known to be caused by mutations that enhance CXCR4 signaling. Our hypothesis is that Mozobil(TM) can be used safely to partially block CXCR4 and treat neutropenia resulting from myelokathexis at doses considerably lower than that being used for CD34+ cell mobilization. This new treatment could also improve other aspects of the disease such as frequent infections, warts, and hypogammaglobulinemia. To test this hypothesis, we propose this Phase I trial of Mozobil (TM) in adults with WHIMS, examining safety and absolute neutrophil count as the primary endpoint.
|Contact: Daniel Velez, R.N.||(301) firstname.lastname@example.org|
|Contact: David H McDermott, M.D.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 firstname.lastname@example.org|
|Principal Investigator:||David H McDermott, M.D.||National Institute of Allergy and Infectious Diseases (NIAID)|